Second primary lung cancer (SPLC) constitute an important dimension of the burden of cancer survivorship that needs to be taken into account when defining strategies for surveillance, prevention and counseling. In last three decades the incidence of SPLC in patients that had a history of a prior cancer out of the respiratory system is estimated 2-8%. Relative risks of SPLC may be smaller than previously reported may benefit from increased surveillance. The goal of this study was to give an overview of SPLC regarding patients’ primary malignancy, their stage of lung cancer presentation and bringing to the light some possible risk factors. Such data will be helpful in calculation of the risk for SPLC as well as handling of risky patients for a better survival. This is a retrospective study for a period of 5 years where all the data that was gathered from clinical cartels of patients with lung cancer were analyzed using Pearson Chi-Square. SPLC represents 2% of all lung cancers diagnosed during the period of study. The prior diagnose of cancer for this patients was breast cancer in 46% of cases, cervix cancer in 40% of cases and the other diagnosis 14% of cases. All the patients have been under oncologic treatment with radio or chemotherapy. 20% of these patients have been smokers prior to first malignancy. The average age of the patients with SPLC was 55 years old. The ratio male to female was 1:10. The most frequent histotype found was adenocarcinoma in 60% of cases meanwhile in all cases with a prior squamous cell cancer of cervix was found squamous cell carcinoma as SPLC. The average period of time from the prime cancer to the SPLC was 3.7 years. 73% of cases with SPLC underwent an anatomical resection of the tumor. This study shows that patients with the higher risk for a SPLC are premenopausal women with breast cancer and cervical cancer. Changes in the prevalence of risk factors and diagnostic techniques may have affected more recent risks. The relative risk of developing SPLC in smokers is unclear. SPLC after oncologic treatment is an issue that raises many questions.